Skip Nav Destination
1-14 of 14
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
ETH-155008, a Novel Selective Dual Inhibitor of FLT3 and CDK4/6 in Preclinical Treatment of Acute Myeloid Leukemia
Changnian Liu, PhD MD, Bin Liu, MSc, Chunping Xu, PhD, Pan Zhang, Bin Li, Bin Ji, Bin Zhang, Qingjun Liu, PhD, James Zhang, MSc, Chengzhi Yu, PhD
Blood (2019) 134 (Supplement_1): 5141.
Comparing Bortezomib-Lenalidomide-Dexamethasone (VRd) with Carfilzomib-Lenalidomide-Dexamethasone (KRd) in the Patients with Newly Diagnosed Multiple Myeloma (NDMM) in Two Observational Studies
Bin Li, PhD, Kaili Ren, PhD, Lei Shen, PhD, Peijie Hou, PhD, Zhenqiang Su, PhD, Alessandra Di Bacco, PhD, Jin-Liern Hong, PhD, Aaron Galaznik, PhD, Ajeeta B Dash, PhD, Victoria Crossland, PhD, Paul Dolin, DPhil, Sandor Szalma, PhD
Blood (2018) 132 (Supplement 1): 3298.
Addition of Ixazomib to an Rd Backbone Improves Clinical Benefit in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) with Non-Canonical NF-KB Activation — Results from the Tourmaline-MM1 Study
Ajeeta B Dash, PhD, Jacob Zhang, PhD, Lei Shen, PhD, Bin Li, PhD, Deborah Berg, RN, MSN, Jianchang Lin, PhD, Hervé Avet-Loiseau, MDPhD, Nizar Bahlis, MD, Philippe Moreau, Paul Richardson, Alessandra Di Bacco, PhD
Blood (2018) 132 (Supplement 1): 473.
Wei Jiang, Xiaoyan Zhou, Zengxia Li, Kaiyu Liu, Weige Wang, Renke Tan, Xiaoji Cong, Jiaoyu Shan, Yanxia Zhan, Zhaomeng Cui, Lizhi Jiang, Quanfu Li, Suqin Shen, Meirong Bai, Yunfeng Cheng, Bin Li, Minjia Tan, Dengke K. Ma, Jun O. Liu, Yongjun Dang
Blood (2018) 131 (12): 1325–1336.
Includes: Supplemental data
Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/Refractory Multiple Myeloma (RRMM)
Alessandra Di Bacco, PhD, Nizar J. Bahlis, MD, Nikhil C Munshi, MD, Hervé Avet-Loiseau, MD PhD, Tamás Masszi, MD, Luísa Viterbo, MD, Ludek Pour, MD PhD, Peter Ganly, BMBCh, PhD, Michele Cavo, MD, Christian Langer, MD, Shaji Kumar, MD, S. Vincent Rajkumar, MD, Deborah Berg, RN, MSN, Jianchang Lin, PhD, Bin Li, Sunita Badola, Lei Shen, Jacob Zhang, Ling Wang, PhD, Dixie-Lee Esseltine, MD, Katarina Luptakova, Helgi van de Velde, MD PhD, Paul G. Richardson, MD, Philippe Moreau
Blood (2016) 128 (22): 243.
Studies of the Proteasome Inhibitor Sensitivity Modulator Tight Junction Protein 1 Highlight a Role for Signaling through the Epidermal Growth Factor Receptor in Determining Proteasome Capacity
Xing-Ding Zhang, PhD, Veerabhadran Baladandayuthapani, PhD, Heather Yan Lin, PhD, George Mulligan, PhD, Bin Li, PhD, Dixie-Lee Esseltine, MD, Lin Qi, PhD, Jian-Liang Xu, PhD, Walter Hunziker, PhD, Bart Barlogie, MD, PhD, Saad Z. Usmani, MD, Qing Zhang, PhD, John Crowley, PhD, Antje Hoering, PhD, Bing-Zong Li, MD, PhD, Huihan Wang, MD, PhD, Jiexin Zhang, M.S., Isere Kuiatse, PhD, Jin-Le Tang, PhD, Jin He, Jing Yang, PhD, Richard Eric Davis, MD, Wencai Ma, PhD, Zhiqiang Wang, PhD, Lin Yang, MD, PhD, Robert Z. Orlowski, PhD MD
Blood (2014) 124 (21): 3414.
Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy
Clinical Trials & Observations
George Mulligan, David I. Lichter, Alessandra Di Bacco, Stephen J. Blakemore, Allison Berger, Erik Koenig, Hugues Bernard, William Trepicchio, Bin Li, Rachel Neuwirth, Nibedita Chattopadhyay, Joseph B. Bolen, Andrew J. Dorner, Helgi van de Velde, Deborah Ricci, Sundar Jagannath, James R. Berenson, Paul G. Richardson, Edward A. Stadtmauer, Robert Z. Orlowski, Sagar Lonial, Kenneth C. Anderson, Pieter Sonneveld, Jesús F. San Miguel, Dixie-Lee Esseltine, Matthew Schu
Blood (2014) 123 (5): 632–639.
Includes: Supplemental data
Mutational Analysis of Tumor Samples From Patients with Relapsed or Refractory Multiple Myeloma (MM) Highlights the Prevalence of RAS/RAF Pathway Activation and Demonstrates Previously Unreported Mutations in Known Cancer Genes
George Mulligan, PhD, David I Lichter, MS, Alessandra Di Bacco, PhD, Stephen J Blakemore, PhD, Allison Berger, PhD, Erik Koenig, Hugues Bernard, William L. Trepicchio, PhD, Bin Li, PhD, Sagar Lonial, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD, Pieter Sonneveld, MD, PhD, Jesús F San Miguel, MD PhD, Dixie-Lee Esseltine, MD, FRCPC, Matthew Schu, MS
Blood (2011) 118 (21): 1377.
TNF-α-Mediated Tumor Promotion Is Characterized by Enhanced Vasculogenesis and Generation of Myeloid/Endothelial Vascular Leukoctyes.
Blood (2007) 110 (11): 3905.
VEGF-VEGF Receptor 1 (Flt-1) Interactions Significantly Modulate Endothelial Progenitor Cell (EPC) Migration but Have Only Minor Effects on the Migration of Differentiated Endothelial Cells.
Blood (2004) 104 (11): 3229.
EPCs Derived from Ex Vivo Expansion of Unmobilized Human Peripheral Blood Co-Express Hematopoietic and Endothelial-Specific Markers and Can Be Derived from Culture of Highly Purified Populations of CD14-Positive Monocytes.
Blood (2004) 104 (11): 2682.
Enhanced Growth Suppression of Philadephia 1 Leukemia Cells in Mice by Targeting Both BCR-ABL and VEGF through the Antisense Strategy.
Blood (2004) 104 (11): 5257.
Hemangiopoietin, a novel human growth factor for the primitive cells of both hematopoietic and endothelial cell lineages
Yong Jun Liu, Shi Hong Lu, Bin Xu, Ren Chi Yang, Qian Ren, Bin Liu, Bin Li, Min Lu, Feng Ying Yan, Zhi Bo Han, Zhong Chao Han
Blood (2004) 103 (12): 4449–4456.
Blood (1997) 90 (5): 1799–1806.